Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$28.1MCash on Hand
49.2mo Cash Runway
Follow GNTA by emailGet an email when GNTA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about GNTA, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 2, 2026 ·
Listing Genenta Science will do business as Saentra Forge and change its Nasdaq ticker from GNTA to SAEN, effective November 4, 2026. The legal name, ADSs and shareholder rights are unchanged, and no shareholder action is required. Form 6-K · SEC filing · Press release
Oct 22, 2026 ·
Legal An Italian court suspended, as an interim measure, the shareholder resolution on board appointments from the June 29, 2026 meeting. The prior board resumed office, and two directors elected at the meeting ceased to serve while the order stands. The company plans to appeal. Form 6-K · SEC filing
Oct 21, 2026 ·
Listing Nasdaq notified Genenta that its ADSs closed below $1.00 for 30 consecutive business days, from September 3, 2026 through October 15, 2026. The company has until April 14, 2027 to regain compliance, and shareholders previously approved a reverse split of 1-for-10 to 1-for-20. Form 6-K · SEC filing · Press release
Oct 13, 2026 ·
Shareholder vote Shareholders at the October 8, 2026 extraordinary meeting voted 53,307,711 for and 20,776,225 against a name change to Saentra Forge S.p.A., but it failed because it did not reach the required more than 50% of total voting rights. Form 6-K · SEC filing
Oct 7, 2026 ·
Legal Court of Milan denied minority shareholders' application for interim suspension of the capital increase tied to the ATC acquisition, so the increase remains effective pending merits proceedings and possible appeal. The underlying civil action is still pending. Form 6-K · SEC filing
Sep 11, 2026 ·
Shareholder vote An extraordinary shareholders' meeting held September 10, 2026 did not vote on a proposal to rename the company Saentra Forge S.p.A. At shareholders' request the proposal was deferred to a reconvened meeting on October 8, 2026, at 5:00 p.m. CET. Form 6-K · SEC filing
Sep 2, 2026 ·
Deal Genenta Science is repositioning as a strategic consolidator targeting majority stakes in privately held Italian aerospace, defense, national security and biosecurity companies. It completed 100% acquisition of A.T.C. S.r.l. Form 6-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
Also used in these trials (approved or third-party drugs, not GNTA's own candidates): Cabozantinib, Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
GNTA holds $28.1M in cash and short-term investments and burns about $1.7M/quarter from operations,
an estimated runway of 49.2 months at that rate (BioRadar estimate, not company guidance).
Share count 23,432,183 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full GNTA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GNTA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.